ArticleFrontiers in neurology2026
Development and validation of a machine learning model based on multi-source clinical data for predicting the risk of early neurological deterioration in patients with ischemic stroke.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Early neurological deterioration (END) is a critical clinical event associated with poor patient outcomes after acute ischemic stroke. Early identification of high-risk patients is crucial for timely clinical management. This study aimed to develop and validate a model for predicting END risk for acute ischemic stroke patients using machine learning algorithms. Methods: This study retrospectively and consecutively enrolled 1,151 patients with acute ischemic stroke from the Stroke Center of Beijing Shunyi District Hospital between January 2021 and December 2024. END was defined as progressive worsening of neurological deficit symptoms after onset. Predictive variables were screened using univariate analysis and multiple feature selection methods (Treebag, Boruta, Bayesian). Nine machine learning algorithms (Decision Tree, Efficient Neural Network, K-Nearest Neighbors, Light Gradient Boosting Machine, Logistic Regression, Multilayer Perceptron, Random Forest, Simplified Support Vector Machine, Extreme Gradient Boosting) were employed to construct prediction models. Hyperparameters were optimized via 10-fold cross-validation, and model performance was evaluated in an internal validation cohort (30% of the sample). Primary evaluation metrics included the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, accuracy, F1 score, and net benefit from decision curve analysis (DCA). The SHAP method was used to interpret the optimal model. Results: A total of 161 patients (14.0%) developed END. Feature selection ultimately identified five key predictors: ischemic stroke etiological subtype, Oxford Community Stroke Project (OCSP) classification, age, atrial fibrillation history, and prior stroke history. In both the development and internal validation cohorts, the logistic regression model demonstrated favorable and stable performance (development cohort AUC: 0.787, 95% CI: 0.735-0.839; internal validation cohort AUC: 0.751, 95% CI: 0.668-0.834), with a low log-loss value. DCA suggested potential clinical utility of the logistic regression model. SHAP analysis revealed that the etiological subtype of ischemic stroke and age were the features contributing most to the model's predictions. Conclusion: This study successfully developed and validated a logistic regression model for predicting END risk. The model incorporates five routinely available clinical variables and demonstrates satisfactory predictive performance and interpretability. The developed online tool may assist clinicians in early risk stratification, providing a reference for personalized intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.